A detailed history of Crossmark Global Holdings, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 5,866 shares of VRTX stock, worth $2.73 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
5,866
Previous 6,164 4.83%
Holding current value
$2.73 Million
Previous $2.89 Million 5.54%
% of portfolio
0.05%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$460.0 - $505.78 $137,080 - $150,722
-298 Reduced 4.83%
5,866 $2.73 Million
Q2 2024

Jul 29, 2024

SELL
$392.81 - $485.53 $13,355 - $16,508
-34 Reduced 0.55%
6,164 $2.89 Million
Q1 2024

May 13, 2024

SELL
$407.69 - $446.08 $934,017 - $1.02 Million
-2,291 Reduced 26.99%
6,198 $2.59 Million
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $157,780 - $188,912
460 Added 5.73%
8,489 $3.45 Million
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $428,474 - $459,236
1,267 Added 18.74%
8,029 $2.9 Million
Q2 2023

Jul 31, 2023

BUY
$314.42 - $351.91 $26,411 - $29,560
84 Added 1.26%
6,762 $2.39 Million
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $809,754 - $923,742
-2,859 Reduced 29.98%
6,678 $2.1 Million
Q4 2022

Jan 19, 2023

BUY
$285.76 - $321.48 $117,161 - $131,806
410 Added 4.49%
9,537 $2.75 Million
Q3 2022

Nov 01, 2022

BUY
$273.83 - $305.53 $101,590 - $113,351
371 Added 4.24%
9,127 $2.64 Million
Q2 2022

Jul 29, 2022

SELL
$234.96 - $292.55 $59,209 - $73,722
-252 Reduced 2.8%
8,756 $2.47 Million
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $280,539 - $330,648
1,267 Added 16.37%
9,008 $2.35 Million
Q4 2021

Jan 10, 2022

SELL
$177.01 - $223.45 $37,172 - $46,924
-210 Reduced 2.64%
7,741 $1.7 Million
Q3 2021

Oct 21, 2021

SELL
$181.39 - $202.99 $28,841 - $32,275
-159 Reduced 1.96%
7,951 $1.44 Million
Q3 2021

Oct 13, 2021

BUY
$181.39 - $202.99 $31,561 - $35,320
174 Added 2.19%
8,110 $453,000
Q2 2021

Jul 21, 2021

SELL
$187.49 - $221.1 $190,302 - $224,416
-1,015 Reduced 11.34%
7,936 $1.6 Million
Q1 2021

Apr 15, 2021

SELL
$207.02 - $241.31 $74,527 - $86,871
-360 Reduced 3.87%
8,951 $1.92 Million
Q4 2020

Jan 14, 2021

SELL
$207.01 - $276.09 $91,705 - $122,307
-443 Reduced 4.54%
9,311 $2.2 Million
Q3 2020

Oct 08, 2020

SELL
$255.65 - $303.1 $3.89 Million - $4.61 Million
-15,207 Reduced 60.92%
9,754 $2.65 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $278,918 - $365,904
1,237 Added 5.21%
24,961 $7.25 Million
Q1 2020

Apr 28, 2020

BUY
$199.77 - $247.81 $47,145 - $58,483
236 Added 1.0%
23,724 $5.65 Million
Q4 2019

Feb 06, 2020

SELL
$166.71 - $223.91 $583,985 - $784,356
-3,503 Reduced 12.98%
23,488 $5.14 Million
Q3 2019

Oct 09, 2019

BUY
$166.23 - $187.09 $6,482 - $7,296
39 Added 0.14%
26,991 $4.57 Million
Q2 2019

Jul 09, 2019

BUY
$164.61 - $190.37 $76,379 - $88,331
464 Added 1.75%
26,952 $4.94 Million
Q1 2019

May 02, 2019

SELL
$163.73 - $194.7 $65,328 - $77,685
-399 Reduced 1.48%
26,488 $4.87 Million
Q4 2018

Jan 31, 2019

SELL
$151.91 - $192.21 $211,306 - $267,364
-1,391 Reduced 4.92%
26,887 $4.46 Million
Q3 2018

Nov 08, 2018

SELL
$167.73 - $192.74 $170,078 - $195,438
-1,014 Reduced 3.46%
28,278 $5.45 Million
Q2 2018

Jul 31, 2018

SELL
$145.72 - $169.96 $115,118 - $134,268
-790 Reduced 2.63%
29,292 $4.98 Million
Q1 2018

Apr 16, 2018

SELL
$151.6 - $177.13 $380,970 - $445,127
-2,513 Reduced 7.71%
30,082 $4.9 Million
Q4 2017

Feb 05, 2018

BUY
$137.28 - $155.55 $1.39 Million - $1.58 Million
10,135 Added 45.12%
32,595 $4.89 Million
Q3 2016

Oct 25, 2017

BUY
N/A
22,460
22,460 $3.42 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Crossmark Global Holdings, Inc. Portfolio

Follow Crossmark Global Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.